Metropolis Healthcare, one of India’s leading diagnostics and pathology service providers, has officially launched its Centre of Genomics a strategic step toward mainstreaming precision diagnostics in the country. The facility is equipped with state of the art sequencing platforms, advanced bioinformatics pipelines, and clinical interpretation workflows to support a wide range of genomic tests.

The Centre of Genomics will focus on several key areas: inherited and rare genetic disorders, cancer genomics (including tumour profiling and actionable mutation panels), pharmacogenomics, and population genetics. By integrating genomic science into routine diagnostic offerings, Metropolis aims to enable earlier detection of disease risks and more personalised therapeutic guidance.

Officials say that this initiative addresses a pressing need in India’s healthcare landscape where genetic testing has traditionally been limited by cost, infrastructure constraints, and specialist interpretation capabilities. With the new centre, clinicians and patients will have access to comprehensive genomic profiles that can inform screening, monitoring and tailored treatment pathways.

In addition to clinical testing services, the Centre of Genomics will support research collaborations, education for healthcare professionals, and data-driven insight into India’s diverse genetic landscape. The facility’s launch aligns with the broader global trend of integrating genomic data into precision medicine strategies, enhancing the ability of healthcare systems to deliver targeted care.

Metropolis Healthcare leadership emphasised that by scaling genomic diagnostics, the company hopes to empower physicians with actionable information, reduce diagnostic delays for complex diseases, and broaden population access to advanced health analytics.